Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension

This study has been completed.
Information provided by:
Bayer Identifier:
First received: September 13, 2005
Last updated: April 19, 2010
Last verified: April 2010
The aim of this study is to monitor long-term safety and tolerability of iloprost aerosol inhalation therapy in patients suffering from pulmonary hypertension.

Condition Intervention Phase
Hypertension, Pulmonary
Drug: Ventavis (Iloprost, BAYQ6256)
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open-label, Uncontrolled, Long-term Surveillance Study of Iloprost Aerosol Inhalation Therapy in the Treatment of Patients With Primary or Secondary Pulmonary Hypertension. Follow-up Program for Patients Who Completed 12 Weeks in Study ME97218/300180.

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Adverse events [ Time Frame: Throughout the whole study ]

Secondary Outcome Measures:
  • Tolerability of treatment [ Time Frame: Over a minimum of 24 months ]

Enrollment: 71
Study Start Date: February 2000
Study Completion Date: August 2005
Arms Assigned Interventions
Experimental: Arm 1 Drug: Ventavis (Iloprost, BAYQ6256)
Inhaled iloprost

Detailed Description:

This study has previously been posted by Schering AG, Germany. Schering AG has been renamed to Bayer Schering Pharma AG, Germany.

Bayer Schering Pharma AG, Germany is the sponsor of the trial.


Ages Eligible for Study:   18 Years to 71 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Completion of the 12-week treatment period of the predecessor Schering study 97218/300180
  • Investigator judged iloprost aerosol therapy warranted as a suitable treatment for the respective patient
  • Negative pregnancy test for females

Exclusion Criteria:

  • Any condition during 12-week treatment period of the predecessor Schering study 97218/300180 that prevents participation in the follow-up safety surveillance study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00185315

Bruxelles, Belgium, 1070
Leuven, Belgium, 3000
Clamart Cedex, France, 92141
Grenoble Cedex 9, France, 38043
Lille, France, 59037
Reims, France, 51092
Tours Cedex, France, 37044
Bologna, BO, Italy, 40138
Montescano, Pavia, Italy, 27040
Pisa, PI, Italy, 56100
Amsterdam, Netherlands, 1081 HV
Warszawa, Poland, 01138
Coimbra, Portugal, 3000-076
Vila Nova de Gaia, Portugal, 4434-506
Barcelona, Spain, 08035
Madrid, Spain, 28041
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Therapeutic Area Head, Bayer Schering Pharma AG Identifier: NCT00185315     History of Changes
Other Study ID Numbers: 90570  303045  Follow-up 90419-300180 
Study First Received: September 13, 2005
Last Updated: April 19, 2010
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Spain: Ministry of Health and Consumption
Portugal: National Pharmacy and Medicines Institute
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products

Additional relevant MeSH terms:
Hypertension, Pulmonary
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Vascular Diseases
Cardiovascular Agents
Hematologic Agents
Pharmacologic Actions
Platelet Aggregation Inhibitors
Therapeutic Uses
Vasodilator Agents processed this record on May 05, 2016